Patents by Inventor Geoffrey S. Kansas

Geoffrey S. Kansas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of chimeric selectins as simultaneous blocking agents for component selectin function
    Patent number: 5834425
    Abstract: Chimeric peptides or polypeptides that combine ligand binding portions from within the lectin and EGF domains of two different selectins are disclosed. The peptides or polypeptides can be constructed solely of the indicated portions of lectin or EGF domains or they can include portions of any of the remaining domains (SCR, transmembrane or cytoplasmic), or the entire extracellular portion, of a generic selectin molecule. The peptides or polypeptides also can be joined to a carrier protein (e.g., a soluble portion of an immunoglobulin molecule) to increase the serum half-life of the therapeutic agent. The chimeric polypeptides can be used as therapeutic agents to antagonize selectin function. They are also useful for screening for agents that are simultaneously antagonists of the function of lectin and EGF domains of different selectins.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: November 10, 1998
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Thomas F. Tedder, Geoffrey S. Kansas
  • Chimeric selectins as simultaneous blocking agents for component selectin function
    Patent number: 5808025
    Abstract: Chimeric peptides or polypeptides that combine ligand binding portions from within the lectin and EGF domains of two different selectins are disclosed. The peptides or polypeptides can be constructed solely of the indicated portions of lectin or EGF domains or they can include portions of any of the remaining domains (SCR, transmembrane or cytoplasmic), or the entire extracellular portion, of a generic selectin molecule. The peptides or polypeptides also can be joined to a carrier protein (e.g., a soluble portion of an immunoglobulin molecule) to increase the serum half-life of the therapeutic agent. The chimeric polypeptides can be used as therapeutic agents to antagonize selectin function. They are also useful for screening for agents that are simultaneously antagonists of the function of lectin and EGF domains of different selectins.
    Type: Grant
    Filed: November 16, 1994
    Date of Patent: September 15, 1998
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Thomas F. Tedder, Geoffrey S. Kansas